1. Home
  2. BBIO vs TPG Comparison

BBIO vs TPG Comparison

Compare BBIO & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • TPG
  • Stock Information
  • Founded
  • BBIO 2015
  • TPG 1992
  • Country
  • BBIO United States
  • TPG United States
  • Employees
  • BBIO N/A
  • TPG N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • TPG Investment Managers
  • Sector
  • BBIO Health Care
  • TPG Finance
  • Exchange
  • BBIO Nasdaq
  • TPG Nasdaq
  • Market Cap
  • BBIO 9.4B
  • TPG 9.1B
  • IPO Year
  • BBIO 2019
  • TPG 2022
  • Fundamental
  • Price
  • BBIO $51.21
  • TPG $61.29
  • Analyst Decision
  • BBIO Strong Buy
  • TPG Buy
  • Analyst Count
  • BBIO 16
  • TPG 13
  • Target Price
  • BBIO $64.44
  • TPG $64.17
  • AVG Volume (30 Days)
  • BBIO 2.2M
  • TPG 1.6M
  • Earning Date
  • BBIO 11-11-2025
  • TPG 11-03-2025
  • Dividend Yield
  • BBIO N/A
  • TPG 2.83%
  • EPS Growth
  • BBIO N/A
  • TPG N/A
  • EPS
  • BBIO N/A
  • TPG N/A
  • Revenue
  • BBIO $235,812,000.00
  • TPG $3,887,230,000.00
  • Revenue This Year
  • BBIO $115.49
  • TPG N/A
  • Revenue Next Year
  • BBIO $64.61
  • TPG $24.40
  • P/E Ratio
  • BBIO N/A
  • TPG N/A
  • Revenue Growth
  • BBIO 7.62
  • TPG 43.35
  • 52 Week Low
  • BBIO $21.72
  • TPG $37.52
  • 52 Week High
  • BBIO $54.60
  • TPG $72.98
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 52.92
  • TPG 56.63
  • Support Level
  • BBIO $52.20
  • TPG $57.79
  • Resistance Level
  • BBIO $54.60
  • TPG $60.13
  • Average True Range (ATR)
  • BBIO 2.26
  • TPG 1.49
  • MACD
  • BBIO -0.06
  • TPG -0.05
  • Stochastic Oscillator
  • BBIO 56.48
  • TPG 76.95

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About TPG TPG Inc.

TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.

Share on Social Networks: